prednisone treatment
Recently Published Documents


TOTAL DOCUMENTS

136
(FIVE YEARS 14)

H-INDEX

26
(FIVE YEARS 1)

Author(s):  
Jing Zhang ◽  
Dan Feng ◽  
Helen Ka-Wai Law ◽  
Ying Wu ◽  
Guang-hua Zhu ◽  
...  

Prednisone is widely used in chronic glomerular diseases, immunological disorders, and rheumatic diseases for its anti-inflammatory and immunosuppressive properties. It is a synthetic glucocorticoid (GC) that shows therapeutic effects after conversion to prednisolone by the liver.


2021 ◽  
Vol 20 ◽  
pp. S288
Author(s):  
M. Yanda ◽  
V. Tomar ◽  
C. Cebotaru ◽  
W. Guggino ◽  
L. Cebotaru

Metabolism ◽  
2021 ◽  
Vol 116 ◽  
pp. 154685
Author(s):  
Danielli Gomes Alves ◽  
Larissa Daiane Lima Bisinoto ◽  
Daniel Ramos Carvalho ◽  
Julia Carvalho Guimarães ◽  
Isabella Rodrigues de Lara Souza ◽  
...  

Metabolism ◽  
2021 ◽  
Vol 116 ◽  
pp. 154655
Author(s):  
Vanessa Tizzo Teixeira ◽  
Mariana Pirani Rocha Machado ◽  
André Cantarelli Vilela ◽  
Gabriel Stefanini ◽  
Gustavo Tadeu Volpato ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-10 ◽  
Author(s):  
Andrew Jamroz ◽  
Michael Berger ◽  
Paul Winston

Objective. The objective of this study was to evaluate prednisone effectiveness on complex regional pain syndrome (CRPS) features in a community-based outpatient rehabilitation setting. Design. A single-centre, retrospective inception cohort design was used. Inclusion criteria were CRPS diagnosis according to the Budapest criteria, involvement of multiple joints, treatment with prednisone, and duration of symptoms less than one year. Typical prednisone treatment was 28-day taper regimen with 60 mg. Patient symptoms and signs were compared before and after treatment. Results. There were 39 patients who met inclusion criteria for analysis. Duration of symptoms before treatment was 80.8 ± 67.7 days. Following treatment, 19 (48.7%) patients reported complete pain resolution, 19 (48.7%) patients reported decreased pain permitting functional use, and 1 (2.6%) patient reported no improvement. All symptoms and signs decreased significantly following oral prednisone treatment (p<0.001). Range of motion (ROM) deficits persisted in 19 (49%) patients. However, 17 of these patients reported functional ROM recovery. Degree of ROM recovery and time-to-treatment had low positive correlation (r = 0.354, p<0.05). Logistic regression did not demonstrate associations among any patient factors and clinical outcomes. Conclusions. These data support short-course prednisone treatment for acute and subacute CRPS with multijoint involvement in a community rehabilitation setting. The association between time-to-treatment and ROM recovery suggests earlier treatment may result in improved ROM outcomes.


Sign in / Sign up

Export Citation Format

Share Document